Financial Review: Sanofi (SNY) versus Adamis Pharmaceuticals Corp (ADMP)
Sanofi (NYSE: SNY) and Adamis Pharmaceuticals Corp (NASDAQ:ADMP) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership.
This table compares Sanofi and Adamis Pharmaceuticals Corp’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Adamis Pharmaceuticals Corp||-130.64%||-72.92%||-51.38%|
Valuation & Earnings
This table compares Sanofi and Adamis Pharmaceuticals Corp’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Sanofi||$42.87 billion||2.84||$12.87 billion||$3.92||12.35|
|Adamis Pharmaceuticals Corp||$9.51 million||13.33||-$21.54 million||N/A||N/A|
Sanofi has higher revenue and earnings than Adamis Pharmaceuticals Corp.
Insider & Institutional Ownership
9.9% of Sanofi shares are held by institutional investors. Comparatively, 11.6% of Adamis Pharmaceuticals Corp shares are held by institutional investors. 1.0% of Sanofi shares are held by company insiders. Comparatively, 12.2% of Adamis Pharmaceuticals Corp shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
Sanofi has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, Adamis Pharmaceuticals Corp has a beta of 0.06, indicating that its stock price is 94% less volatile than the S&P 500.
Sanofi pays an annual dividend of $1.10 per share and has a dividend yield of 2.3%. Adamis Pharmaceuticals Corp does not pay a dividend. Sanofi pays out 28.1% of its earnings in the form of a dividend.
This is a summary of recent ratings and price targets for Sanofi and Adamis Pharmaceuticals Corp, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Adamis Pharmaceuticals Corp||0||0||2||0||3.00|
Sanofi presently has a consensus target price of $53.50, suggesting a potential upside of 10.47%. Adamis Pharmaceuticals Corp has a consensus target price of $7.50, suggesting a potential upside of 63.04%. Given Adamis Pharmaceuticals Corp’s stronger consensus rating and higher possible upside, analysts clearly believe Adamis Pharmaceuticals Corp is more favorable than Sanofi.
Sanofi beats Adamis Pharmaceuticals Corp on 8 of the 14 factors compared between the two stocks.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company’s vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company’s vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.
Adamis Pharmaceuticals Corp Company Profile
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company’s lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.